دورية أكاديمية
Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial.
| العنوان: | Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial. |
|---|---|
| المؤلفون: | Grant SC; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA., Kostakoglu L, Kris MG, Yeh SD, Larson SM, Finn RD, Oettgen HF, Cheung NV |
| المصدر: | European journal of nuclear medicine [Eur J Nucl Med] 1996 Feb; Vol. 23 (2), pp. 145-9. |
| نوع المنشور: | Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7606882 Publication Model: Print Cited Medium: Print ISSN: 0340-6997 (Print) Linking ISSN: 03406997 NLM ISO Abbreviation: Eur J Nucl Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Heidelberg : Springer Verlag Original Publication: Heidelburg, Springer International. |
| مواضيع طبية MeSH: | Carcinoma, Small Cell/*diagnostic imaging , Lung Neoplasms/*diagnostic imaging , Radioimmunodetection/*methods, Carcinoma, Small Cell/secondary ; Female ; Gangliosides/immunology ; Humans ; Iodine Radioisotopes ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Pilot Projects ; Tomography, Emission-Computed, Single-Photon |
| مستخلص: | The present study evaluated the ability of the anti-GD2 ganglioside monoclonal antibody 3F8 to target tumor sites in patients with small-cell lung cancer (SCLC). Of 12 patients entered into the trial, ten received intravenous 3F8 labeled with 2 or 10 mCi iodine-131. The first five patients had recurrent or progressive disease after chemotherapy. Subsequent patients were studied before starting chemotherapy. Radionuclide scans were performed on days 1, 2, and 3 post-infusion and once between day 5 and day 7. Four patients underwent single-photon emission tomography (SPET) imaging. Radionuclide scans demonstrated localization to all known sites of disease, other than small brain metastases in one patient. SPET/CT scan fusion images confirmed precise localization. No significant toxicity was observed. Mean serum half-life was 64.2 h. Analysis of specimens from one patient who died of unrelated causes 6 days post-infusion confirmed the scan results. The present study demonstrates that 3F8 targets SCLC sites in patients. Further studies of anti-GD2 antibodies with higher doses of antibody and radionuclide are warranted to evaluate their role in SCLC. |
| References: | J Natl Cancer Inst. 1986 Sep;77(3):739-45. (PMID: 3091900) Cancer Res. 1987 Dec 15;47(24 Pt 1):6600-5. (PMID: 3499978) Proc Natl Acad Sci U S A. 1985 Feb;82(4):1242-6. (PMID: 3883355) J Cell Biol. 1986 Mar;102(3):688-96. (PMID: 3005335) Cancer Res. 1986 Oct;46(10):5112-8. (PMID: 3019521) J Clin Oncol. 1992 Apr;10(4):671-2. (PMID: 1548529) Proc Natl Acad Sci U S A. 1984 Sep;81(18):5767-71. (PMID: 6385004) J Clin Oncol. 1987 Sep;5(9):1430-40. (PMID: 3625258) |
| معلومات مُعتمدة: | CA-05826 United States CA NCI NIH HHS; CA-09149-15 United States CA NCI NIH HHS; CA-33409 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (Gangliosides) 0 (Iodine Radioisotopes) 65988-71-8 (ganglioside, GD2) |
| تواريخ الأحداث: | Date Created: 19960201 Date Completed: 19961105 Latest Revision: 20190826 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1007/BF01731837 |
| PMID: | 8925848 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. كن أول من يترك تعليقا!